Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NEOVACS S.A.
CureVac Frames Comeback With Dutch Biotech Buy
The German firm is buying Frame Cancer Therapeutics in a deal valued at €32m, with CEO Franz-Werner Haas claiming that it will help the firm in its search for promising neoantigens for its mRNA cancer vaccine programs.
Pipeline Watch: Phase III Progress With Tecentriq, Rolontis And ADV7103
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Neovacs CEO: 'We Need A Phase III Partner Now' To Progress Our Lupus Asset
French biotech says it has adequate Phase II data to design a pivotal study with regulators, but needs trial funding and a big pharma partner.
Deals Shaping The Medical Industry, March 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- Neostell SAS
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.